Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05581745 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A2 to O Lung Transplants

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from University Health Network, Toronto

Record History

  1. Primary completion pushed from Dec 31, 2026 to Dec 31, 2027 Eligibility criteria expanded, about 7 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 7 words
  2. Primary completion date: Dec 31, 2025 to Dec 31, 2026 Completion date: Dec 31, 2032 to Dec 31, 2033v5 Show 1 more changeShow less
    • Completion date: Dec 31, 2032 to Dec 31, 2033
  3. 2 versions Re-verified since Dec 8, 2022, no change to tracked fieldsv3-v4
  4. Primary endpoints revised (11)v2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.
Trial Details
NCT Number NCT05581745
Lead Sponsor University Health Network, Toronto
Conditions Lung Transplant, ABO Incompatibility
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov